Roche’s fenebrutinib maintains near-complete suppression of disease activity and disability progression for up to two years in people with relapsing…


Basel, 30 May 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new, 96-week data for fenebrutinib demonstrating that patients with relapsing multiple sclerosis (RMS) maintained no disability progression and low levels of disease activity for up to two years. The latest results for this investigational Bruton’s tyrosine kinase (BTK) inhibitor from the Phase II FENopta open-label extension (OLE) study were presented at the Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting in Phoenix, Arizona.

Visit link:
Roche’s fenebrutinib maintains near-complete suppression of disease activity and disability progression for up to two years in people with relapsing...

Related Posts